检索结果 - Mark D. Pegram

Refine Results
  1. 1
    Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

    Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer 由 Mark D. Pegram, Christian Jackisch, Stephen Johnston

    出版 2023
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Triple negative breast cancer: unmet medical needs

    Triple negative breast cancer: unmet medical needs 由 Sumanta K. Pal, Barrett H. Childs, Mark D. Pegram

    出版 2010
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

    Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs 由 Richard J. Pietras, Mark D. Pegram, Richard S. Finn, Daniel A Maneval, Dennis J. Slamon

    出版 1998
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

    The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells 由 Mark D. Pegram, Richard Finn, Karo K. Arzoo, Malgorzata Beryt, Richard J. Pietras, Dennis J. Slamon

    出版 1997
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Hydrogel Pore‐Size Modulation for Enhanced Single‐Cell Western Blotting

    Hydrogel Pore‐Size Modulation for Enhanced Single‐Cell Western Blotting 由 Todd A. Duncombe, Chi‐Chih Kang, Santanu Maity, Toby M. Ward, Mark D. Pegram, Niren Murthy, Amy E. Herr

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Extracellular Vesicle–Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity

    Extracellular Vesicle–Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity 由 Alexis V. Forterre, Jing‐Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D. Pegram, Stefanie S. Jeffrey, A. Matin

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Role of Fcγ receptors in HER2-targeted breast cancer therapy

    Role of Fcγ receptors in HER2-targeted breast cancer therapy 由 Antonino Musolino, William J. Gradishar, Hope S. Rugo, Jeffrey L. Nordstrom, Edwin P. Rock, Fernanda I. Arnaldez, Mark D. Pegram

    出版 2022
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  8. 8
    Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

    Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831 由 Nadine Norton, Rebecca M. Olson, Mark D. Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer 由 Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Immune cell repertoires in breast cancer patients after adjuvant chemotherapy

    Immune cell repertoires in breast cancer patients after adjuvant chemotherapy 由 Claire E. Gustafson, Rohit R. Jadhav, Wenqiang Cao, Qian Qi, Mark D. Pegram, Lü Tian, Cornelia M. Weyand, Jörg J. Goronzy

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study 由 Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Nuhad K. Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P. Kirschbrown, Priya Kumthekar

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review

    Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review 由 Hope S. Rugo, Giuseppe Curigliano, Fátima Cardoso, WJ Gradishar, Mark D. Pegram, C.H.H. Barrios, J. Cortés Castán, Eduardo J. Pennella, Rafael Muniz

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–pos... 由 Xavier Pivot, Mark D. Pegram, Javier Cortés, Diana Lüftner, Gary H. Lyman, Giuseppe Curigliano, Igor Bondarenko, Ye Chan Yoon, Younsoo Kim, Chul Kim

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens 由 Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu, Lee S. Schwartzberg, Michael Arbushites, Julie Maltzman, John Forster, S. D. Rubin, Steven H. Stein, Harold J. Burstein

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation

    Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation 由 Jing‐Hung Wang, Alexis V. Forterre, Jinjing Zhao, Daniel O. Frimannsson, Alain Delcayre, Travis J. Antes, Bradley Efron, Stefanie S. Jeffrey, Mark D. Pegram, A. Matin

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

    Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer 由 José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall... 由 Véronique Dièras, David Miles, Sunil Verma, Mark D. Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim T. Blackwell, Silke Hoersch, Jin Xu, Marjorie Green, Luca Gianni

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

    Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 由 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton

    出版 2001
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer

    Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer 由 Marzia Locatelli, Philippe Aftimos, Elizabeth Claire Dees, Patricia LoRusso, Mark D. Pegram, Ahmad Awada, Bo Huang, Rossano Cesari, Yuqiu Jiang, M. Naveed Shaik, Kenneth A. Kern, Giuseppe Curigliano

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

    First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer 由 Mark D. Pegram, Erika Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, Manish R. Patel

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: